Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs

Pfizer Japan President Akihisa Harada Pfizer Japan suffered a 6.6% sales dip in FY2017 through November last year as it was slammed by generic erosions despite growth of its major products, including the pain medication Lyrica (pregabalin), the company said...read more